A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: ARV-471|DRUG: ARV-471 in combination with palbociclib (IBRANCE®)
Sponsor: Arvinas Estrogen Receptor, Inc.
Collaborators: Pfizer